Trial Profile
Conversion from a twice-daily tacrolimus (tac) regimen to a once-daily tacorlimus exended-release formulation (TacXL) regimen : Pharamcokinetic studies in stable cystic fibrosis (CF) and non-CF patients having received a pulmonary transplant
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 21 Oct 2013
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary)
- Indications Lung transplant rejection
- Focus Pharmacokinetics
- Acronyms Tac-XL
- 20 Jun 2011 New trial record